The Role of the Social Network in Fatal Opioid Overdose Prevention: The Former Opioid User’s Perspective

Abstract

Naloxone hydrochloride (naloxone) is an effective fatal opioid overdose prevention strategy. The study findings describe former opioid users’ phenomenological perspectives regarding their social network, settings of use, and the benefits and barriers to naloxone. Participants (N = 25) with at least 6 months of recovery time (M = 30, SD = 14.40) were interviewed individually for an average of 21 (SD = 5.13) min. The sample was predominately male, Caucasian, and non-Hispanic with an average age of 37 (SD = 7.22) years. Interview transcripts were analyzed using systematic thematic analysis. During their period of opioid use, most participants differentiated the members of their social network as other people who use opioids (PWUO) and nonusers. The participants described several opportunities for members of their social network to use naloxone. They discussed barriers to naloxone use specific to PWUO within their social network such as apathy toward overdose. Future interventions should be tailored to address naloxone use barriers specific to PWUO and nonusers.

Keywords

opioids overdose naloxone social networks former opioid users

Get full access to this article

View all access options for this article.

References

Ataiants

Mazzella

Roth

A. M.

Sell

R. L.

Robinson

L. F.

Lankenau

S. E.

(2020). Overdose response among trained and untrained women with a history of illicit drug use: A mixed-methods examination. Drugs: Education, Prevention and Policy, 1–12. https://doi.org/10.1080/09687637.2020.1818691

Bagley

S. M.

Peterson

Cheng

D. M.

Jose

Quinn

O’Connor

P. G.

Walley

A. Y.

(2015). Overdose education and naloxone rescue kits for family members of individuals who use opioids: Characteristics, motivations, and naloxone use. Substance Abuse, 36(2), 149–154. https://doi.org/10.1080/08897077.2014.989352

Banta-Green

C. J.

Beletsky

Schoeppe

J. A.

Coffin

P. O.

Kuszler

P. C.

(2013). Police officers’ and paramedics’ experiences with overdose and their knowledge and opinions of Washington State’s drug overdose–naloxone–Good Samaritan law. Journal of Urban Health, 90(6), 1102–1111. https://doi.org/10.1007/s11524-013-9814-y

Bennett

A. S.

Freeman

Des Jarlais

D. C.

Aronson

I. D.

(2020). Reasons people who use opioids do not accept or carry no-cost naloxone: Qualitative interview study. JMIR Formative Research, 4(12), e22411. https://doi.org/10.2196/22411

Bonar

E. E.

Bohnert

A. S.

(2016). Perceived severity of and susceptibility to overdose among injection drug users: Relationships with overdose history. Substance Use & Misuse, 51(10), 1379–1383. https://doi.org/10.3109/10826084.2016.1168447

Bowles

J. M.

Smith

L. R.

Verdugo

S. R.

Wagner

K. D.

Davidson

P. J.

(2020). “Generally, you get 86’ed because you’re a liability”: An application of Integrated Threat Theory to frequently witnessed overdoses and social distancing responses. Social Science & Medicine, 260, 113190. https://doi.org/10.1016/j.socscimed.2020.113190

Bowman

Engelman

Kozio

Mahoney

Maxwell

McKenzie

(2014). The Rhode Island community responds to opioid overdose deaths. Rhode Island Medical Journal, 97(10), 34–37. http://www.rimed.org/rimedicaljournal/2014/10/2014-10-34-dadt-bowman.pdf

Campo-Flores

Elinson

(2014, February). Heroin use, and deaths, rise. The Wall Street Journal, p. A5. http://www.wsj.com/articles/SB10001424052702304851104579361250012275942

Clark

A. K.

Wilder

C. M.

Winstanley

E. L.

(2014). A systematic review of community opioid overdose prevention and naloxone distribution programs. Journal of Addiction Medicine, 8(3), 153–163. https://doi.org/10.1097/ADM.0000000000000034

10.

Corso

Townley

(2016). Intervention, treatment, and prevention strategies to address opioid use disorders in rural areas: A primer on opportunities for Medicaid-safety net collaboration. https://www.nashp.org/wp-content/uploads/2016/09/Rural-Opioid-Primer.pdf

11.

Creswell

(2012). Analyzing and interpreting qualitative data. In Educational research: Planning, conducting, and evaluating quantitative and qualitative research (4th ed.). Pearson Education. http://lcwu.edu.pk/ocd/cfiles/TESOL/MS-TSL-505/EducationalResearchPlanningConductingandEvaluatingQuantitativeandQualitativeResearch.pdf

12.

Davis

Webb

Burris

(2013). Changing law from barrier to facilitator of opioid overdose prevention. The Journal of Law, Medicine & Ethics, 41(Suppl. 1), 33–36. https://doi.org/10.1111/jlme.12035

13.

Easterling

K. W.

Mack

K. A.

Jones

C. M.

(2016). Location of fatal prescription opioid-related deaths in 12 states, 2008–2010: Implications for prevention programs. Journal of Safety Research, 58, 105–109. https://doi.org/10.1016/j.jsr.2016.07.004

14.

Evans

T. I.

Hadland

S. E.

Clark

M. A.

Green

T. C.

Marshall

B. D.

(2016). Factors associated with knowledge of a Good Samaritan Law among young adults who use prescription opioids non-medically. Harm Reduction Journal, 13(1), Article 24. https://doi.org/10.1186/s12954-016-0113-2

15.

Evoy

K. E.

Hill

L. G.

Davis

C. S.

(2021). Considering the potential benefits of over-the-counter naloxone. Integrated Pharmacy Research and Practice, 10, 13–21. https://doi.org/10.2147/IPRP.S244709

16.

Giglio

R. E.

DiMaggio

C. J.

(2015). Effectiveness of bystander naloxone administration and overdose education programs: A meta-analysis. Injury Epidemiology, 2(1), 1–9. https://doi.org/10.1186/s40621-015-0041-8

17.

Goldberg

S. A.

Liao

V. T.

Albert

Fawcett

Narovec

C. M.

Dworkis

D. A.

Eyre

A. J.

DiClemente

Weiner

S. G.

(2017). 39 feasibility of bystander administration of public access naloxone for opioid overdose. Annals of Emergency Medicine, 70(4), S16. https://doi.org/10.1016/j.annemergmed.2017.07.063

18.

Green

T. C.

Bowman

S. E.

Ray

McKenzie

Lord

S. E.

Rich

J. D.

(2015). Development of an incarceration-specific overdose prevention video: Staying alive on the outside. Health Education Journal, 74(5), 627–637. https://doi.org/10.1177/0017896914550321

19.

Green

T. C.

Case

Fiske

Baird

Cabral

Burstein

Cabral

Burstein

Schwartz

Potter

Walley

A. Y.

Bratberg

(2017). Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. Journal of the American Pharmacists Association, 57(2), S19–S27. https://doi.org/10.1016/j.japh.2017.01.013

20.

Harris

M. T.

Bagley

S. M.

Maschke

Schoenberger

S. F.

Sampath

Walley

A. Y.

Gunn

C. M.

(2021). Competing risks of women and men who use fentanyl: “The number one thing I worry about would be my safety and number two would be overdose.” Journal of Substance Abuse Treatment, 125, 108313. https://doi.org/10.1016/j.jsat.2021.108313

21.

Heavey

S. C.

Burstein

Moore

Homish

G. G.

(2018). Overdose education and naloxone distribution program attendees: Who attends, what do they know, and how do they feel? Journal of Public Health Management and Practice, 24(1), 63–68. https://doi.org/10.1097/PHH.0000000000000538

22.

Jones

J. D.

Campbell

Metz

V. E.

Comer

S. D.

(2017). No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. Addictive Behaviors, 71, 104–106. https://doi.org/10.1016/j.addbeh.2017.03.008

23.

Jones

J. D.

Roux

Stancliff

Matthews

Comer

S. D.

(2014). Brief overdose education can significantly increase accurate recognition of opioid overdose among heroin users. International Journal of Drug Policy, 25(1), 166–170. https://doi.org/10.1016/j.drugpo.2013.05.006

24.

Kahn

L. S.

Wozniak

Vest

B. M.

Moore

(2020). “Narcan encounters”: Overdose and naloxone rescue experiences among people who use opioids. Substance Abuse, 1–14. https://doi.org/10.1080/08897077.2020.1748165

25.

Katzman

J. G.

Greenberg

N. H.

Takeda

M. Y.

Balasch

M. M.

(2019). Characteristics of patients with opioid use disorder associated with performing overdose reversals in the community: An opioid treatment program analysis. Journal of Addiction Medicine, 13(2), 131–138. https://doi.org/10.1097/ADM.0000000000000461

26.

Keane

Egan

J. E.

Hawk

(2018). Effects of naloxone distribution to likely bystanders: Results of an agent-based model. International Journal of Drug Policy, 55, 61–69. https://doi.org/10.1016/j.drugpo.2018.02.008

27.

Khatiwoda

Proeschold-Bell

R. J.

Meade

C. S.

Park

L. P.

Proescholdbell

(2018). Facilitators and barriers to naloxone kit use among opioid-dependent patients enrolled in medication assisted therapy clinics in North Carolina. North Carolina Medical Journal, 79(3), 149–155. https://doi.org/10.18043/ncm.79.3.149

28.

Kim

Miller

Veloso

Lin

McFarland

(2020). Prevalence and disparities in opioid overdose response training among people who inject drugs, San Francisco: Naloxone training among injectors in San Francisco. International Journal of Drug Policy, 2020, 102778. https://doi.org/10.1016/j.drugpo.2020.102778

29.

Kuehn

B. M.

(2014). Back from the brink: Groups urge wide use of opioid antidote to avert overdoses. Journal of the American Medical Association, 311(6), 560–561. https://doi.org/10.1001/jama.2014.481

30.

Lankenau

S. E.

Wagner

K. D.

Silva

Kecojevic

Iverson

McNeely

Kral

A. H.

(2013). Injection drug users trained by overdose prevention programs: Responses to witnessed overdoses. Journal of Community Health, 38(1), 133–141. https://doi.org/10.1007/s10900-012-9591-7

31.

Latkin

C. A.

Edwards

Davey-Rothwell

Yang

Tobin

K. E.

(2018). The relationship between drug use settings, roles in the drug economy, and witnessing a drug overdose in Baltimore, Maryland. Substance Abuse, 39(3), 384–389. https://doi.org/10.1080/08897077.2018.1439801

32.

Latkin

C. A.

Gicquelais

R. E.

Clyde

Dayton

Davey-Rothwell

German

Falade-Nwulia

Saleem

Fingerhood

Tobin

(2019). Stigma and drug use settings as correlates of self-reported, non-fatal overdose among people who use drugs in Baltimore, Maryland. International Journal of Drug Policy, 68, 86–92. https://doi.org/10.1016/j.drugpo.2019.03.012

33.

McAuley

Munro

Taylor

(2018). “Once I’d done it once it was like writing your name”: Lived experience of take-home naloxone administration by people who inject drugs. International Journal of Drug Policy, 58, 46–54. https://doi.org/10.1016/j.drugpo.2018.05.002

34.

Reed

Wagner

K. D.

Tran

N. K.

Brady

K. A.

Shinefeld

Roth

(2019). Prevalence and correlates of carrying naloxone among a community-based sample of opioid-using people who inject drugs. International Journal of Drug Policy, 73, 32–35. https://doi.org/10.1016/j.drugpo.2019.07.010

35.

Richert

(2015). Wasted, overdosed, or beyond saving—To act or not to act? Heroin users’ views, assessments, and responses to witnessed overdoses in Malmö, Sweden. International Journal of Drug Policy, 26(1), 92–99. https://doi.org/10.1016/j.drugpo.2014.07.006

36.

Rochester

Graboyes

(2020). Experiences of people who use drugs with naloxone administration: A qualitative study. Drugs: Education, Prevention and Policy, 1–8. https://doi.org/10.1080/09687637.2020.1855116

37.

Tippey

K. G.

Yovanoff

McGrath

L. S.

Sneeringer

(2019). Comparative human factors evaluation of two nasal naloxone administration devices: NARCAN® nasal spray and naloxone prefilled syringe with nasal atomizer. Pain and Therapy, 8(1), 89–98. https://doi.org/10.1007/s40122-019-0118-0

38.

Tobin

Clyde

Davey-Rothwell

Latkin

(2018). Awareness and access to naloxone necessary but not sufficient: Examining gaps in the naloxone cascade. International Journal of Drug Policy, 59, 94–97. https://doi.org/10.1016/j.drugpo.2018.07.003

39.

Tyler

A. M.

(2018). A retrospective analysis of an opiate education and naloxone distribution program. Doctor of Nursing Practice Projects, 24. https://spark.siue.edu/dnpprojects/24

40.

van Dorp

E. L.

Yassen

Dahan

(2007). Naloxone treatment in opioid addiction: The risks and benefits. Expert Opinion on Drug Safety, 6(2), 125–132. https://doi.org/10.1517/14740338.6.2.125

41.

Wagner

K. D.

Davidson

P. J.

Iverson

Washburn

Burke

Kral

A. H.

McNeeley

Jackson Bloom

Lankenau

S. E.

(2014). “I felt like a superhero”: The experience of responding to drug overdose among individuals trained in overdose prevention. International Journal of Drug Policy, 25(1), 157–165. https://doi.org/10.1016/j.drugpo.2013.07.003

42.

Walley

A. Y.

Doe-Simkins

Quinn

Pierce

Xuan

Ozonoff

(2013). Opioid overdose prevention with intranasal naloxone among people who take methadone. Journal of Substance Abuse Treatment, 44(2), 241–247. https://doi.org/10.1016/j.jsat.2012.07.004

43.

Wheeler

Jones

T. S.

Gilbert

M. K.

Davidson

P. J.

(2015). Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. Morbidity and Mortality Weekly Report (MMWR), 64(23), 631–635. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584734/

44.

Williams

A. V.

Strang

Marsden

(2013). Development of Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales for take-home naloxone training evaluation. Drug and Alcohol Dependence, 132(1), 383–386. https://doi.org/10.1016/j.drugalcdep.2013.02.007

45.

Wilson

Kariisa

Seth

Smith

IV. Davis

N. L.

(2020). Drug and opioid-involved overdose deaths—United States, 2017–2018. Morbidity and Mortality Weekly Report (MMWR), 69, 290–297. http://dx.doi.org/10.15585/mmwr.mm6911a4